SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，但不一定是研究者所在的机构。 SELECT是一项III期、双盲、安慰剂对照临床试验，旨在评估硒和维生素E（单独或联合）对前列腺癌发病率的影响，由常规临床管理确定。 累积目标是全国范围内32，400名55岁或以上的健康男性（非洲裔美国男性年龄为50岁或以上）。 研究持续时间为12年，统一的累积期为5年。 受试者将从随机化时开始接受研究补充剂，直至试验期结束，时间为7 - 12年，具体取决于受试者的随机化时间。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SELECT is a Phase III, double blind, placebo-controlled clinical trial designed to assess the effect of selenium and vitamin E (individually and in combination) on the incidence of prostate cancer as determined by routine clinical management. The accrual goal is 32,400 healthy men nationwide who are 55 years old or older (age 50 years or older for African-American men). Study duration will be twelve years with a five-year uniform accrual period. Participants will receive study supplements from the time of their randomization until the end of the trial period, between seven and twelve years depending upon when the participant was randomized.